Please login to the form below
gouty arthritis
This page shows the latest gouty arthritis news and features for those working in and with pharma, biotech and healthcare.
CV data sets up Novartis' Ilaris for blockbuster sales
Ilaris is an interleukin-1 beta inhibitor and has been on sale since 2009, gradually picking up approvals for a range of inflammatory diseases including juvenile-onset rheumatoid arthritis, gouty arthritis
Latest news
-
Novartis' Ilaris wins three new FDA approvals
The three new indications add to Ilaris' existing approvals in Adult-Onset Still's Disease (AOSD), gouty arthritis, and autoinflammatory condition Systemic Juvenile Idiopathic Arthritis ( SJIA), the most aggressive form of ... juvenile arthritis.
-
Grunenthal to market MSD’s pain drug
The drug has been available in Europe via MSD since the early 2000s and is indicated to relieve pain in people with osteoarthritis, rheumatoid arthritis and acute gouty arthritis.
-
Novartis wins childhood arthritis indication for Ilaris in EU
EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis. ... gouty arthritis, which is a painful inflammation of the joints.
-
Novartis gets FDA green light for new Ilaris indication
Immunotherapeutic wins US approval for severe form of childhood arthritis. The US FDA has cleared another indication for Novartis' fast-growing immunotherapeutic Ilaris, this time giving the nod to its use ... arthritis. Efforts to get a gouty arthritis
-
Novartis' Ilaris cleared for gouty arthritis in EU
First biologic drug approved for condition in Europe. Novartis' Ilaris has become the first biologic drug to be approved in the EU to treat the symptoms of gouty arthritis in another ... The European Commission (EC) cleared llaris (canakizumab) for the
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
- COVID-19 could be key in identifying viruses with pandemic potential
- Novo Nordisk Foundation commits €127m for new cell therapy facility
- Alzheimer’s Research UK launches ‘Change The Ending’ campaign
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
No results were found
PMHub
Videum Health
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
